ArticleJournal of thoracic disease2021
CHMP4C regulates lung squamous carcinogenesis and progression through cell cycle pathway.
Article in Journal of thoracic disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Elevated levels of SLC38A1 are correlated with an unfavorable prognosis, as well as accelerated cell proliferation and metastasis in lung adenocarcinoma.BMC cancer · 2026Article
- CHMP4C deletion inhibits the proliferation and metastasis of hypopharyngeal squamous cell carcinoma through the Wnt/β-catenin/EMT signaling pathway.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- CHMP4C promotes pancreatic cancer progression by inhibiting necroptosis via the RIPK1/RIPK3/MLKL pathway.Journal of advanced research · 2025Article
- The role and mechanism of CHMP4C in poor prognosis and drug sensitivity of lung adenocarcinoma.Discover oncology · 2025Article
- Exploring the clinical and biological significance of the cell cycle-related gene CHMP4C in prostate cancer.BMC medical genomics · 2024Article
- Elevated CDC45 Expression Predicts Poorer Overall Survival Prognoses and Worse Immune Responses for Kidney Renal Clear Cell Carcinoma via Single-Cell and Bulk RNA-Sequencing.Biochemical genetics · 2024Article
- A Novel Defined Necroptosis-Related Genes Prognostic Signature for Predicting Prognosis and Treatment of Osteosarcoma.Biochemical genetics · 2024Article
- Chromatin-modifying protein 4C (CHMP4C) affects breast cancer cell growth and doxorubicin resistance as a potential breast cancer therapeutic target.The Journal of antibiotics · 2024Article
- Establishment of a prognostic risk model for osteosarcoma and mechanistic investigation.Frontiers in pharmacology · 2024Article
- Article
- CHMP4C as a novel marker regulates prostate cancer progression through cycle pathways and contributes to immunotherapy.Frontiers in oncology · 2023Article
- Construction of T cell exhaustion model for predicting survival and immunotherapy effect of bladder cancer based on WGCNA.Frontiers in oncology · 2023Article
- Comprehensive analysis of circulating cell-free RNAs in blood for diagnosing non-small cell lung cancer.Computational and structural biotechnology journal · 2023Article
- Identification of pyroptosis-related genes and long non-coding RNAs signatures in osteosarcoma.Cancer cell international · 2022Article
- Genomic analysis of the endosomal sorting required for transport complex III pathway genes as therapeutic and prognostic biomarkers for endometrial carcinoma.Translational cancer research · 2022Article
- Identification and Validation of Prognostic Model for Pancreatic Ductal Adenocarcinoma Based on Necroptosis-Related Genes.Frontiers in genetics · 2022Article
- Telomere maintenance-related genes are important for survival prediction and subtype identification in bladder cancer.Frontiers in genetics · 2022Article
- Identification of a Pyroptosis-Related Gene Signature and Effect of Silencing theInternational journal of general medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is a common kind of human malignancies. Lung squamous cell carcinoma (LUSC) is a key subtype of lung cancer. Cell cycle plays an important role in the development and occurrence of LUSC, however, there is still a lack of cell cycle-related genes in LUSC diagnosis and prediction of prognosis.
methodsWe identified differentially expressed genes (DEGs) with "limma" package in R software, and determined the biomarkers of LUSC in diagnosing by performing receiver operating characteristic (ROC) curve analysis, the biomarker effectiveness in diagnosing LUSC was assessed by performing five-fold cross-validation with logistic regression. Kaplan-Meier plot and the nomogram assessed the relationship between the biomarker and patient survival, and WB and qRT-PCR detected the biomarker expression in cells and tissues. Flow cytometry detects the role of the biomarker in the cell cycle.
resultsIntegration analysis with The Cancer Genome Atlas (TCGA) database obtained a unique gene related to cell cycle in LUSC (Charged multivesicular body protein 4C, CHMP4C), and the protein of CHMP4C was highly expressed in LUSC tissues. ROC analysis indicated that CHMP4C was a biomarker for the diagnosis of LUSC. Bioinformatic analysis indicated that CHMP4C might be associated with cell cycle in LUSC. CHMP4C knockdown resulted in S-phase arrest of cells with LUSC. According to the survival rate analysis, CHMP4C overexpression indicated poor prognosis in patients with LUSC.
conclusionsCHMP4C regulates the proliferation process of tumor cells through the cell cycle. It can be used as a potential diagnostic and prognostic biomarker for LUSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.